Terlivaz Injection, Powder, Lyophilized, For Solution
FDA Label NDC 43825-200

30 label sections · Submitted to the FDA by Keenova Hospital Products Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Keenova Hospital Products Inc. for the product Terlivaz (NDC 43825-200). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious or fatal respiratory failure, 1 indications and usage, 2.1 important considerations prior to initiating and during therapy, 2.2 recommended dosage, 2.3 preparation and administration, 3 dosage forms and strengths, 4 contraindications, 5.1 serious or fatal respiratory failure, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.